Analysis of the effect and cost-effectiveness of entecavir (Runzhong) in the treatment of hepatitis B before and after the implementation of the '4+7' urban consumption procurement policy

Real-World Research for the Efficacy and Safety Evaluation of Chinese Medicines with Volume Purchase

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023945

Enrollment

Unknown

Registered

2019-06-19

Start date

2019-06-20

Completion date

Unknown

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

Case series:entecavir (Runzhong)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Comply with the diagnostic criteria for chronic hepatitis B and the initial antiviral treatment standard in the Guidelines for Prevention and Treatment of Chronic Hepatitis B (2015 Update); 2. Aged = 18 years; 3. No other varieties of antiviral Drug wihin 12 weeks; 4. Entecavir dose of 0.5mg fasting orally once a day.

Exclusion criteria

Exclusion criteria: 1. Combined with other types of liver disease, HIV, liver cancer or decompensated liver disease patients; 2. Taking immunosuppressive agents or glucocorticoids within 24 weeks.

Design outcomes

Primary

Measure	Time frame
efficacy and drug economy;	—

Contacts

Public ContactZhao Yanling

The Fifth Medical Center of the PLA General Hospital

zhaoyl2855@126.com+86 13681208998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026